Enzo Biochem (NYSE:ENZ) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note published on Wednesday. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Performance

Shares of ENZ opened at $1.16 on Wednesday. Enzo Biochem has a 1 year low of $0.99 and a 1 year high of $1.50. The stock’s fifty day moving average price is $1.13 and its two-hundred day moving average price is $1.11.

Enzo Biochem Dividend Announcement

The firm also recently announced a dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 15th will be paid a $0.10 dividend. The ex-dividend date is Friday, November 15th.

Institutional Trading of Enzo Biochem

An institutional investor recently raised its position in Enzo Biochem stock. XTX Topco Ltd boosted its holdings in Enzo Biochem, Inc. (NYSE:ENZ) by 94.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,262 shares of the medical research company’s stock after buying an additional 13,735 shares during the period. XTX Topco Ltd owned approximately 0.05% of Enzo Biochem worth $31,000 as of its most recent filing with the Securities and Exchange Commission. 36.90% of the stock is currently owned by institutional investors.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.